Rgenix

24 articles about Rgenix

• RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand

  9/30/2021

  Inspirna, Inc. announced today its corporate name change from Rgenix to Inspirna and announced the appointment of Dieter Weinand to its Board of Directors, where he will serve as Chairman.

• RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting

  6/22/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-019, RGENIX’s pre-clinical antibody program in development. RGENIX’s abstract, “In Vivo Safety and Efficacy of RGX-019, a MerTK Targeting Monoclonal Antibody” was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting

• RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting

  6/22/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors”

• 

  Clinical Catch-Up: May 31-June 5

  6/8/2020

  As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial

  5/29/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting data showing clinical activity in patients with advanced colorectal (CRC) tumors from a clinical trial of RGX-202, a first-in-class small molecule that inhibits a novel canc

• 

  AACR Annual Meeting News: Merck, RGENIX, Verastem and More

  4/29/2020

  In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.

• RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting

  4/27/2020

  RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR); Initial results from the phase 1b RGX-104 plus Docetaxel combination dose escalation cohorts” was accepte

• Rgenix Names Industry Veteran to Chief Medical Officer Role

  9/16/2019

  Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry

• Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting

  4/3/2019

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting pre-clinical data from ongoing research of RGX-019,

• Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting

  4/1/2019

  Rgenix, Inc. announced that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting.

• 

  BioSpace Movers and Shakers for Dec. 3

  12/3/2018

  Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.

• Rgenix Appoints Serial Entrepreneur and Senior Executive Peter Van Vlasselaer to Board of Directors

  11/27/2018

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced the appointment of Peter Van Vlasselaer, Ph.D., to its Board of Directors.

• Rgenix Treats First Patient in Phase 1 Trial of RGX-202

  10/31/2018

  Rgenix, Inc. today announced it has treated the first patient in a Phase 1 a/b study of RGX-202.

• Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs

  10/9/2018

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced that it has raised $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs

• Rgenix Presents Data on Phase I Clinical Activity For RGX-104 at the 2018 ASCO Annual Meeting

  6/4/2018

  RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab.

• Rgenix to Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting

  5/31/2018

  Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018 Annual Meeting of the American Society of Clinical Oncology. The meeting will take place in Chicago from June 1 through June 5.

• 

  AACR Meeting Brief: Sosei, Verseon, Rgenix, Xencor and others

  4/18/2018

  The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.

• Rgenix Presents Pre-Clinical Data on RGX-202 at the 2018 AACR Annual Meeting

  4/18/2018

  Pre-clinical data indicates RGX-202 suppresses cancer growth in colon and pancreatic cancer models Rgenix plans to initiate a clinical study of RGX-202 in patients with advanced gastrointestinal malignancies

• Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity

  1/12/2018

  Rgenix announced today the publication of clinical and pre-clinical results by research collaborators at Rgenix and The Rockefeller University.